Sanofi India Limited Fundamental Analysis (BSE: SANOFI.BO)
Sanofi India Limited Fundamental Analysis (BSE: SANOFI.BO)
Sanofi India Limited (BSE: SANOFI.BO) shows moderate financial fundamentals with a PE ratio of 25.19, profit margin of 17.47%, and ROE of 38.86%. The company generates $17.7B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 95.0/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze SANOFI.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentSANOFI.BO demonstrates superior asset utilization.
Valuation Score
ModerateSANOFI.BO shows balanced valuation metrics.
Growth Score
ModerateSANOFI.BO shows steady but slowing expansion.
Financial Health Score
ExcellentSANOFI.BO maintains a strong and stable balance sheet.
Profitability Score
ExcellentSANOFI.BO achieves industry-leading margins.
Key Financial Metrics
Is SANOFI.BO Expensive or Cheap?
P/E Ratio
SANOFI.BO trades at 25.19 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, SANOFI.BO's PEG of -3.21 indicates potential undervaluation.
Price to Book
The market values Sanofi India Limited at 10.42 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 18.03 times EBITDA. This signals the market has high growth expectations.
How Well Does SANOFI.BO Make Money?
Net Profit Margin
For every $100 in sales, Sanofi India Limited keeps $17.47 as profit after all expenses.
Operating Margin
Core operations generate 27.76 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $38.86 in profit for every $100 of shareholder equity.
ROA
Sanofi India Limited generates $24.69 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sanofi India Limited generates limited operating cash flow of $1.46B, signaling weaker underlying cash strength.
Free Cash Flow
Sanofi India Limited produces free cash flow of $1.38B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $60.05 in free cash annually.
FCF Yield
SANOFI.BO converts 1.77% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
25.19
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-3.21
vs 25 benchmark
P/B Ratio
Price to book value ratio
10.42
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.40
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.63
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.39
vs 25 benchmark
ROA
Return on assets percentage
0.25
vs 25 benchmark
ROCE
Return on capital employed
0.65
vs 25 benchmark
How SANOFI.BO Stacks Against Its Sector Peers
| Metric | SANOFI.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 25.19 | 29.04 | Better (Cheaper) |
| ROE | 38.86% | 484.00% | Weak |
| Net Margin | 17.47% | -71879.00% (disorted) | Strong |
| Debt/Equity | 0.02 | 0.84 | Strong (Low Leverage) |
| Current Ratio | 1.63 | 5.20 | Neutral |
| ROA | 24.69% | -27.00% (disorted) | Strong |
SANOFI.BO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sanofi India Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation